Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care (PRODEFAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00794196|
Recruitment Status : Completed
First Posted : November 19, 2008
Results First Posted : August 15, 2016
Last Update Posted : November 22, 2016
|Condition or disease||Intervention/treatment||Phase|
|Depression||Behavioral: Pharmaceutical care program for antidepressant treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||179 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||November 2012|
No Intervention: Usual Care
The control group will be receiving usual medical and pharmaceutical care.
Experimental: Intervention Group
Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
Behavioral: Pharmaceutical care program for antidepressant treatment
The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
Other Name: PRODEFAR group
- Adherence to Antidepressant Medication [ Time Frame: At 3 and 6 months ]Adherence to antidepressant medication was measured through Pharmacy records
- Patient Wellbeing [ Time Frame: 0, 3 and 6 months ]
Patient wellbeing EUROQOL5D scale is used to evaluate health-related quality of life.
The answers given to EUROQOL5D allow for the description 243 unique health states which can be converted into EQ-5D index anchored at 0 for death and 1 for perfect health.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00794196
|Primary Care Center Gavà 1|
|Gava, Barcelona, Spain, 08850|
|Primary Care Center Doctor Bartomeu Fabres Anglada|
|Gavà, Barcelona, Spain, 08850|
|Principal Investigator:||Antoni Serrano, MD PhD||Foundation Sant Joan de Deu|